日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease

尼达尼布对局限性皮肤系统性硬化症和间质性肺病患者的影响

期刊:Rheumatology
影响因子:4.4
doi:10.1093/rheumatology/kead280
Allanore, Yannick; Khanna, Dinesh; Smith, Vanessa; Aringer, Martin; Hoffmann-Vold, Anna-Maria; Kuwana, Masataka; Merkel, Peter A; Stock, Christian; Sambevski, Steven; Denton, Christopher P
特发性肺纤维化
系统性硬化症
免疫/内分泌
发表日期：2024
文献求助 收藏

Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis

ANCHOR-RA 研究设计：一项针对类风湿性关节炎患者进行间质性肺病筛查的多国横断面研究

期刊:BMC Rheumatology
影响因子:2.5
doi:10.1186/s41927-024-00389-4
Sparks, Jeffrey A; Dieudé, Philippe; Hoffmann-Vold, Anna-Maria; Burmester, Gerd R; Walsh, Simon Lf; Kreuter, Michael; Stock, Christian; Sambevski, Steven; Alves, Margarida; Emery, Paul
关节炎
特发性肺纤维化
发表日期：2024
文献求助 收藏

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

尼达尼布对伴有系统性硬化症相关间质性肺病和快速进展危险因素患者的疗效

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2022-002859
Khanna, Dinesh; Maher, Toby M; Volkmann, Elizabeth R; Allanore, Yannick; Smith, Vanessa; Assassi, Shervin; Kreuter, Michael; Hoffmann-Vold, Anna-Maria; Kuwana, Masataka; Stock, Christian; Alves, Margarida; Sambevski, Steven; Denton, Christopher P
特发性肺纤维化
系统性硬化症
免疫/内分泌
发表日期：2023
文献求助 收藏

Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial

SENSCIS试验中系统性硬化症相关间质性肺病患者的呼吸困难和咳嗽

期刊:Rheumatology
影响因子:4.4
doi:10.1093/rheumatology/keac091
Volkmann, Elizabeth R; Kreuter, Michael; Hoffmann-Vold, Anna M; Wijsenbeek, Marlies; Smith, Vanessa; Khanna, Dinesh; Denton, Christopher P; Wuyts, Wim A; Miede, Corinna; Alves, Margarida; Sambevski, Steven; Allanore, Yannick
特发性肺纤维化
系统性硬化症
免疫/内分泌
发表日期：2022
文献求助 收藏

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

EMPA-REG OUTCOME 试验表明，恩格列净可降低心血管风险谱系中心力衰竭患者的死亡率和住院率。

期刊:Circulation
影响因子:38.6
doi:10.1161/CIRCULATIONAHA.118.037778
Fitchett, David; Inzucchi, Silvio E; Cannon, Christopher P; McGuire, Darren K; Scirica, Benjamin M; Johansen, Odd Erik; Sambevski, Steven; Kaspers, Stefan; Pfarr, Egon; George, Jyothis T; Zinman, Bernard
心血管
心力衰竭
发表日期：2019
文献求助 收藏

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care

恩格列净与常规临床护理中心力衰竭住院风险

期刊:Circulation
影响因子:38.6
doi:10.1161/CIRCULATIONAHA.118.039177
Patorno, Elisabetta; Pawar, Ajinkya; Franklin, Jessica M; Najafzadeh, Mehdi; Déruaz-Luyet, Anouk; Brodovicz, Kimberly G; Sambevski, Steven; Bessette, Lily G; Santiago Ortiz, Adrian J; Kulldorff, Martin; Schneeweiss, Sebastian
心力衰竭
心血管
发表日期：2019
文献求助 收藏